Vedolizumab-Induced Acute Interstitial Nephritis in Ulcerative Colitis

Subhaharan, Deloshaan; Ramaswamy, Pradeep Kakkadasam; Francisco, Sewwandi; Ishaq, Naveed

doi:10.14309/crj.0000000000000788

Cited by 5 publications

(6 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Vedolizumab-induced AIN has been described in several case reports in the past few years 7–9. These are summarised in table 1.…”

Section: Discussionmentioning

confidence: 99%

“…The efficacy of vedolizumab has previously been demonstrated in the GEMINI trials for both induction and maintenance of remission in refractory UC 3. Vedolizumab-induced AIN has been demonstrated in prior case reports including where vedolizumab was successfully retrialled with high dose prednisone prophylaxis at the time of infusion 7–9. AIN associated with other integrin inhibitors has not been reported to date.…”

Section: Introductionmentioning

confidence: 88%

“…Given the temporal relationship to his dose of vedolizumab and his first AKI, and the fact that this drug has been associated with interstitial nephritis in the past,7–9 a vedolizumab-induced AIN was felt to be the most likely diagnosis.…”

Section: Differential Diagnosismentioning

confidence: 99%

See 2 more Smart Citations

Vedolizumab-induced acute interstitial nephritis with failure of steroid prophylaxis on vedolizumab rechallenge

O'Leary,

Wong,

Wilson

2023

BMJ Case Rep

View full text Add to dashboard Cite

Acute interstitial nephritis (AIN) is a common cause of acute kidney injury and renal failure. It is typically drug induced but can also be idiopathic or secondary to chronic infective or inflammatory conditions. Recent case reports suggest vedolizumab can be a causative agent for AIN. We report the case of a young man who presented with renal failure, fevers and constitutional symptoms. He had a complex history of refractory ulcerative colitis, prior colectomy and ileo-pouch-anal anastomosis with recurrent pouchitis. He had been receiving regular vedolizumab infusions for 6 months by the time of his presentation. A renal biopsy 4 months into his follow-up demonstrated AIN. Steroid prophylaxis with vedolizumab was trialled but ultimately failed, with worsening AIN and incomplete renal function recovery. To our knowledge, this is the first case of vedolizumab-induced AIN demonstrating a failure of steroid prophylaxis to prevent recurrence of AIN following vedolizumab rechallenge.

show abstract

“…Vedolizumab-induced AIN has been described in several case reports in the past few years 7–9. These are summarised in table 1.…”

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 88%

See 1 more Smart Citation

Vedolizumab-induced acute interstitial nephritis with failure of steroid prophylaxis on vedolizumab rechallenge

O'Leary,

Wong,

Wilson

2023

BMJ Case Rep

View full text Add to dashboard Cite

show abstract

“…In patients with moderate to severe IBD, more specifically UC, Vedolizumab is considered one of the first-line therapies [14]. Vedolizumab is a humanized anti-alpha-4-beta-7 integrin monoclonal antibody that has been found to be safe and effective in IBD patients, and minimize the risk of renal side effects [15]. In a retrospective study conducted by Dubinsky et al, patients on vedolizumab were at a higher risk of developing EIM than patients on anti-TNF [16].…”

Section: Discussionmentioning

confidence: 99%

Risk of Nephrolithiasis in Patients with Inflammatory Bowel Disease Receiving Biologic Treatment

Alameddine,

Abi Melhem,

Dimachkie

et al. 2023

JCM

View full text Add to dashboard Cite

Introduction: Inflammatory bowel disease is a chronic inflammatory disorder of the gastrointestinal tract. Biologic drugs target specific molecules in the body’s immune system to control inflammation. Recent studies have suggested a potential link between their use and an increased risk of nephrolithiasis. We conducted a study to further investigate this association. Methods: The study used multiple logistic regression analysis to assess the association between the use of biologic drugs and nephrolithiasis. A p-value of <0.05 was considered statistically significant. SAS 9.4 was used for statistical analysis. Results: The final sample consisted of 22,895 cases, among which 5603 (24.51%) were receiving at least one biologic drug. The biologic drugs received were as follows: Adalimumab 2437 (10.66%), Infliximab 1996 (8.73%), Vedolizumab 1397 (6.11%), Ustekinumab 1304 (5.70%); Tofacitinib, 308 (1.35%); Certolizumab, 248 (1.08%); and Golimumab, 121 (0.53%). There were 1780 (7.74%) patients with Nephrolithiasis: 438 (8.0%) patients were receiving biologic treatment. We found that the use of Vedolizumab (OR = 1.307, 95% CI 1.076–1.588, p = 0.0071) increased the odds of Nephrolithiasis by 31%. Conclusion: Vedolizumab use was associated with an increased risk of nephrolithiasis. The use of two or more biologic drugs also increased the risk compared to no biologic treatment.

show abstract

“…(41,42) Podobně byl také vedolizumab, humanizovaná monoklonální protilátka, která se specificky váže na integrin α4β7, v několika kazuistických sděleních označen za příčinu léky indukované TIN u pacienta s IBD. (43)(44)(45)…”

Section: Léky Indukované Postižení Ledvin U Pacientů S Ibdunclassified

Renal involvement in pediatric inflammatory bowel disease

Švábová,

Bauer,

Gonsorčíková

et al. 2023

Ces-slov Pediat

View full text Add to dashboard Cite

Pediatrická klinika, 1. lékařská fakulta, Univerzita Karlova a Fakultní Thomayerova nemocnice souhrn Švábová e, bauer D, Gonsorčíková L, Zieg J. renální postižení u pediatrických pacientů se zánětlivým střevním onemocněním Incidence zánětlivých střevních onemocnění celosvětově stoupá, a to zejména v dětské populaci. Zánětlivá střevní onemocnění mohou být doprovázena extraintestinální manifestací. Nejčastěji jsou kromě střev postiženy klouby, kůže, žlučové cesty a oči. Dalším orgánem, který může být v rámci základního onemocnění zasažen, jsou ledviny. Nejobvyklejší renální projevy zánětlivých střevních onemocnění zahrnují nefrolitiázu a dále také onemocnění renálního parenchymu -tubulointersticiální nefritidu, glomerulonefritidu a amyloidózu. V našem přehledovém článku se zaměřujeme na spektrum renálních chorob asociovaných se zánětlivými střevními onemocněními.

show abstract

Vedolizumab-Induced Acute Interstitial Nephritis in Ulcerative Colitis

Cited by 5 publications

References 17 publications

Vedolizumab-induced acute interstitial nephritis with failure of steroid prophylaxis on vedolizumab rechallenge

Vedolizumab-induced acute interstitial nephritis with failure of steroid prophylaxis on vedolizumab rechallenge

Risk of Nephrolithiasis in Patients with Inflammatory Bowel Disease Receiving Biologic Treatment

Renal involvement in pediatric inflammatory bowel disease

Contact Info

Product

Resources

About